UV Filter Benzophenone-2 Associated With Higher Total and LDL Cholesterol in Older Adults, Study Finds
In 76 healthy older adults in China, higher urine levels of benzophenone-2 were associated with higher LDL cholesterol and apolipoprotein B, and also with higher HDL cholesterol. European Union scientists say benzophenone-2 in cosmetics may be a risk to consumers, citing signs of genotoxicity and hormone activity, and the European Commission has proposed a ban. The Australian Sunscreen Council is calling for oxybenzone and other benzophenone UV filters to be banned from Australian sunscreen.

In a study of 76 healthy older adults in China, each interquartile-range (IQR) increase in urine levels of benzophenone-2 (BP-2) was associated with 8.0% higher LDL cholesterol and 8.7% higher apolipoprotein B (ApoB), a protein that carries cholesterol in the blood (Situ et al., 2026, Sec. 3.2; Supplementary Table S1). The European Commission's Scientific Committee on Consumer Safety (SCCS) concluded that "the use of Benzophenone-2 in cosmetic products may pose a risk to the consumer because of the indications for genotoxicity and endocrine activity" (Scientific Committee on Consumer Safety [SCCS], 2025, p. 3), and the European Commission has proposed banning BP-2 from cosmetic products (European Commission, 2026, recital 12). The Australian Sunscreen Council is calling for oxybenzone and other benzophenone UV filters to be banned from Australian sunscreen, where oxybenzone is still used (Therapeutic Goods (Permissible Ingredients) Determination (No. 3) 2026, item 3645).
BP-2 was also associated with 7.6% higher total cholesterol, 6.6% higher non-HDL cholesterol, 9.2% higher HDL cholesterol and 9.6% higher apolipoprotein A1 (ApoA1) (Situ et al., 2026, Sec. 3.2; Supplementary Table S1). The authors wrote that this "concurrent elevation of both proatherogenic and antiatherogenic lipid markers is not a classical lipid profile alteration and may reflect a global upregulation of lipid synthesis or a compensatory response, suggesting increased overall lipid metabolic burden" (Situ et al., 2026, Sec. 4.1).
BP-2 was also associated with a 1.89% increase in QRS duration, a measure of the heart's electrical activity on an electrocardiogram (Situ et al., 2026, Sec. 3.9; Supplementary Table S19). The authors wrote that it suggests "subclinical electrical alterations in older adults" (Situ et al., 2026, Sec. 4.3).
The authors, who studied chemicals from personal care products (PCPs), concluded: "These multifaceted findings suggest associations between PCP exposures and serum lipid profiles, and highlight the potential contribution to cardiovascular risk" (Situ et al., 2026, Abstract).
The same study measured oxybenzone, also called benzophenone-3 (BP-3). Each IQR increase in oxybenzone was associated with 17.1% higher apolipoprotein E4 (ApoE4), another fat-carrying protein in the blood (Situ et al., 2026, p. 628; Supplementary Table S1). Oxybenzone was not associated with cholesterol or the other blood fats measured, and the ApoE4 result did not hold in every check the authors ran (Situ et al., 2026, Supplementary Tables S1, S5, S7).
What the TGA found
This is a failure of the Therapeutic Goods Administration (TGA). Its own May 2025 safety review, released under FOI 26-2156, concluded that "oxybenzone is not deemed to present a low risk to human health and safety" (Therapeutic Goods Administration [TGA], 2025a, p. 61 of 74). The review recommended "that oxybenzone is listed in the Poisons Standard" (TGA, 2025a, p. 61 of 74), and in July 2025 the TGA proposed "a new CAUTION (Schedule 5) entry for oxybenzone", with exemptions for some products (TGA, 2025b, p. 11). In March 2026 the TGA said its interim decision "will be published and subject to public consultation in early 2026" (TGA, 2026a, p. 17). None has been published. The TGA's Sunscreen ingredients page, last updated on 11 September 2026, now says: "The interim decision on these ingredients will be published and subject to public consultation by the end of 2026" (TGA, 2026b). A September 2025 brief for the TGA's scheduling delegate recorded: "Oxybenzone is not currently scheduled and has not been previously considered for scheduling" (TGA, 2025c, p. 4 of 9). Today oxybenzone is still used in Australian sunscreens (Therapeutic Goods (Permissible Ingredients) Determination (No. 3) 2026, item 3645), and it is still unscheduled.
What the study found
The study, by Situ and colleagues, was published in Environmental Health Perspectives in 2026. The researchers followed 76 healthy adults aged 60 to 69 in Jinan, China, at five monthly visits from September 2018 to January 2019, and measured personal care product chemicals in their urine and blood fats in their serum (Situ et al., 2026, Abstract; Sec. 2.1). They describe these products as including "preservatives, ultraviolet filters, disinfectants, and fragrances" (Situ et al., 2026, Sec. 1).
The authors wrote: "Together, these limitations preclude causal conclusions" (Situ et al., 2026, p. 634). When they excluded samples with chemical levels below the detection limit, leaving 139 samples, "the associations were attenuated" (Situ et al., 2026, Sec. 4.1): all six of BP-2's associations with blood fats were no longer statistically significant after correction for multiple testing (Situ et al., 2026, Supplementary Table S5). When women and men were analysed separately, BP-2's associations with total cholesterol, HDL cholesterol, ApoA1 and ApoB held in women, but none held in men (Situ et al., 2026, Supplementary Table S7). They wrote: "Our findings suggest PCPs as potential contributors to cardiometabolic risks in aging populations" (Situ et al., 2026, Sec. 5).
What other regulators have done
The European Union restricts oxybenzone, listed in its rules as Benzophenone-3, as a UV filter in cosmetic products under Commission Regulation (EU) 2022/1176 (European Commission, 2022, p. 52, recital 8). The regulation records that a call for data was launched in 2019 "in light of concerns related to potential endocrine disrupting properties of Benzophenone-3 and Octocrylene, when used as UV filters in cosmetic products" (European Commission, 2022, p. 51, recital 2), and the European Commission concluded that "there is potential risk to human health arising from the use of Benzophenone-3 and Octocrylene as UV filters in cosmetic products in the concentrations currently allowed" (European Commission, 2022, p. 52, recital 8).
In Australia, the Therapeutic Goods Administration's own safety review, released under Freedom of Information, states: "Benzophenone, an important impurity and degradant of octocrylene, is considered to be genotoxic, carcinogenic and shown to disrupt endocrine signalling" (TGA, 2025a, p. 54 of 74).
The European Commission says BP-2 "is used in cosmetic products as a UV filter, light stabiliser and fragrance" (European Commission, 2026, recital 7). Its proposed ban on BP-2 in cosmetic products is a draft, sent to the Council of the European Union on 21 September 2026 (European Commission, 2026), and is not yet law: the European Parliament and the Council can object until 18 December 2026 (European Parliament, 2026, pp. 17–18).
The Danish Environmental Protection Agency concluded that oxybenzone "is an endocrine disruptor for the human health and for the environment" (Danish Environmental Protection Agency, 2025, p. 9). In 2025 Denmark added BP-2 to List III of the endocrine disruptor lists (Endocrine Disruptor List, n.d.-a), which covers "Substances considered, by the evaluating National Authority, to have endocrine disrupting properties" (Endocrine Disruptor List, n.d.-b).
The United Kingdom's Office for Product Safety and Standards (OPSS) has called for data on BP-2, saying: "OPSS would like to evaluate the safety of these ingredients in cosmetic products due to their suspected endocrine disrupting properties" (Office for Product Safety and Standards [OPSS], 2026).
The United States Food and Drug Administration (FDA) wrote in 2021: "Given the available data showing significant transdermal absorption and systemic availability of oxybenzone, as well as the potential for endocrine activity, we propose that sunscreens containing oxybenzone are not GRASE", GRASE meaning generally recognised as safe and effective (U.S. Food and Drug Administration [FDA], 2021, p. 44). Transdermal means through the skin.
What the Australian Sunscreen Council is calling for
The Australian Sunscreen Council points to TGA FOI 26-2156, which revealed the regulator's own May 2025 safety review said "Oxybenzone was carcinogenic in mice (bone marrow, spleen, kidney and liver)" (TGA, 2025a, p. 32 of 74), and that in rats, "Liver was the major distribution site of oxybenzone" (TGA, 2025a, p. 23 of 74). The Council is calling on the TGA to ban oxybenzone and other benzophenone UV filters in Australian sunscreen.
Non-nano zinc oxide is the only broad-spectrum UV filter that is reef safe and Generally Recognized As Safe and Effective (GRASE) by the US FDA (National Oceanic and Atmospheric Administration [NOAA], n.d.; National Park Service [NPS], n.d.; FDA, 2019, p. 6206; Beasley & Meyer, 2010; Hanrahan, 2012). On its own it protects across the full UVA and UVB range, including long UVA (Beasley & Meyer, 2010; Hanrahan, 2012).
The United States (FDA) now classifies bemotrizinol as generally recognized as safe and effective for over-the-counter sunscreens, under conditions set in its June 2026 final order (FDA, 2026, p. 8). The final order says "FDA concludes that bemotrizinol is GRASE for use as an active ingredient in OTC sunscreen drug products under the conditions set forth in Section IX of this document, and other applicable requirements." (FDA, 2026, p. 8). In its December 2025 proposed order, the FDA described bemotrizinol as exhibiting "high photostability and broad-spectrum coverage across the UVB (280 to 320 nanometers (nm)) and UVA (320 to 400 nm) ranges" (FDA, 2025, p. 5).
Other sun protection
Sunscreen is one part of sun protection. Cancer Council Australia says "Sunscreen is not a suit of armour and should be used with the other four sun protection measures" (Cancer Council Australia, n.d.). Its advice is to wear sun-protective clothing: "Choose clothing that covers as much skin as possible (think shirts with long sleeves)." Some clothing "may carry an ultraviolet protection factor (UPF), which is a guarantee of how much UV protection a fabric provides" (Cancer Council Australia, n.d.). Add a "broad-brimmed hat", "Seek shade" and wear "close-fitting wraparound sunglasses, that meet Australian Standards" (Cancer Council Australia, n.d.). The Australian Radiation Protection and Nuclear Safety Agency (ARPANSA) says "There is more to sun protection than just sunscreen. No sunscreen provides complete protection against UVR" (ARPANSA, n.d.).
About the Australian Sunscreen Council
The Australian Sunscreen Council is a registered Australian charity dedicated to improving the health of everyday Australians through UV education, research and evidence-based sun safety initiatives.
As Australia’s peak industry body for sunscreen safety, the Council works with scientists, medical professionals, industry experts and policymakers to advance sunscreen safety, support independent research, improve public understanding of UV exposure and promote stronger public-health standards.
ABN 64 692 134 982
Australian Sunscreen Council Editorial Team
The Council is supported by an Expert Group and may draw on advice from one or more members depending on the subject matter of a particular article, submission or publication. Members listed by the Council include (Australian Sunscreen Council, n.d.):
Dr Craig Downs, Executive Director, Haereticus Environmental Laboratory
Dr Russell Hills, cosmetic and laser dermatologist and Mohs specialist
Dr Denis Dudley, obstetrician-gynaecologist and endocrinologist
Dr Abhinandan “Rocky” Chowdhury, toxicologist
Dr Leslie Laquieze, sunscreen testing and photoprotection
Mgr. Mehrdad Mirzaei, pharmacist and photoprotection researcher
Joseph DiNardo, cosmetic toxicologist
Dr Alan Jones, skin cancer physician
Camila Biato Stopa, MSc, cosmetic scientist and pharmacist
Acknowledgment
Grok was used in the creation of this article. Always read the sunscreen label and use only as directed. Sunscreen is only one part of sun protection. Avoid prolonged sun exposure and wear protective clothing, hats, and eyewear.
References
Australian Radiation Protection and Nuclear Safety Agency. (n.d.). Sun protection using sunscreens. Retrieved November 1, 2026, from https://www.arpansa.gov.au/understanding-radiation/radiation-sources/more-radiation-sources/sun-protection-sunscreen
Australian Sunscreen Council. (n.d.). Scientific experts in sunscreen safety. Retrieved October 24, 2026, from https://www.australiansunscreencouncil.org/scientific-experts-sunscreen-safety
Beasley, D. G., & Meyer, T. A. (2010). Characterization of the UVA protection provided by avobenzone, zinc oxide, and titanium dioxide in broad-spectrum sunscreen products. American Journal of Clinical Dermatology, 11(6), 413–421. https://doi.org/10.2165/11537050-000000000-00000
Cancer Council Australia. (n.d.). Protect your skin in five simple steps. Retrieved November 1, 2026, from https://www.cancer.org.au/save-your-skin/five-sunsmart-steps
Danish Environmental Protection Agency. (2025, August 6). Substance evaluation conclusion and evaluation report for oxybenzone (BP-3), EC 205-031-5 [Denmark, evaluating Member State Competent Authority, REACH substance evaluation]. European Chemicals Agency. https://chem.echa.europa.eu/api-activity-list/v1/substanceEvaluation/documents?name=3d9250c025a0c88b1b70d3fcdef2c4b1_SEV-205-031-5-1_Conclusion_public.pdf
Endocrine Disruptor List. (n.d.-a). Benzophenone-2 (BP-2). Retrieved October 24, 2026, from https://edlists.org/substance/benzophenone-2-bp-2
Endocrine Disruptor List. (n.d.-b). Substances considered, by the evaluating National Authority, to have endocrine disrupting properties [List III]. Retrieved October 24, 2026, from https://edlists.org/the-ed-lists/list-iii-substances-identified-as-endocrine-disruptors-by-participating-national-authorities
European Commission. (2022). Commission Regulation (EU) 2022/1176 of 7 July 2022 amending Regulation (EC) No 1223/2009 of the European Parliament and of the Council as regards the use of certain UV filters in cosmetic products. Official Journal of the European Union, L 183, 51–53. https://eur-lex.europa.eu/eli/reg/2022/1176/oj
European Commission. (2026). Draft Commission Regulation (EU) …/… amending Regulation (EC) No 1223/2009 of the European Parliament and of the Council as regards the use in cosmetic products of certain substances, including those classified as carcinogenic, mutagenic or toxic for reproduction (D(2026) 117774) [Council of the European Union document ST 13462/26, cover note of 21 September 2026]. https://data.consilium.europa.eu/doc/document/ST-13462-2026-INIT/en/pdf
European Parliament. (2026, October 7). Minutes of the sitting of 7 October 2026 (PV-10-2026-10-07). https://data.europarl.europa.eu/distribution/doc/PV-10-2026-10-07_en.pdf
Hanrahan, J. R. (2012). Sunscreens. Australian Prescriber, 35(5), 148–151. https://doi.org/10.18773/austprescr.2012.068
National Oceanic and Atmospheric Administration. (n.d.). Skincare chemicals and marine life. National Ocean Service. Retrieved October 10, 2026, from https://oceanservice.noaa.gov/news/sunscreen-corals.html
National Park Service. (n.d.). Sunscreen. U.S. Department of the Interior. Retrieved October 10, 2026, from https://www.nps.gov/subjects/oceans/sunscreen.htm
Office for Product Safety and Standards. (2026, February 5). Call for data: Safety of cosmetic ingredients [Web page, last updated 5 February 2026]. GOV.UK. Retrieved October 12, 2026, from https://www.gov.uk/government/news/call-for-data-safety-of-cosmetic-ingredients
Scientific Committee on Consumer Safety. (2025). Scientific advice on Benzophenone-2 and Benzophenone-5 (SCCS/1679/25; final version adopted 26 June 2025, corrigendum adopted 26 March 2026). European Commission. https://health.ec.europa.eu/document/download/abb0eaac-a20b-43b1-8226-fb73d7167c6c_en?filename=sccs_o_301.pdf
Situ, Y., Guo, X., Ren, H., Qian, J., Li, C., Li, C., Tang, X., Zhang, J., Wang, X., Wang, M., Liang, Y., Qi, C., Chen, L., Shao, K., Cui, H., Tang, S., Mao, C., & Shi, X. (2026). Multiomics insights linking personal care products exposure to serum lipid profiles in older adults: The China BAPE study. Environmental Health Perspectives, 134(6), 624–638. https://doi.org/10.1021/EHP.6c00011. Licensed under CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Therapeutic Goods Administration. (2025a, May). Safety review of seven active sunscreen ingredients (Version 1.0) [Released under FOI 26-2156, Document 4]. https://www.tga.gov.au/sites/default/files/2026-06/FOI%2026-2156.PDF
Therapeutic Goods Administration. (2025b, July 8). Consultation: Proposed amendments to the Poisons Standard in relation to homosalate, oxybenzone and benzophenone – Joint ACMS-ACCS #41 meeting, September 2025. https://consultations.tga.gov.au/tga/scheduling-pre-meeting-sunscreen-substances-sep-25/user_uploads/pre-meeting-public-notice---joint-41---homosalate-oxybenzone-benzophenone---sep-2025-1.pdf
Therapeutic Goods Administration. (2025c, September 17). Pre-meeting brief on agenda papers: Joint Advisory Committee on Chemicals and Medicines Scheduling (Joint ACMS-ACCS) #41 [Released under FOI 26-3100, Document 1]. https://www.tga.gov.au/sites/default/files/2026-07/FOI%2026-3100.pdf
Therapeutic Goods Administration. (2026a, March). Consultation: Seeking feedback on improvements to the regulation of sunscreens in Australia (Version 1.0). https://consultations.tga.gov.au/tga/improvements-to-regulation-of-sunscreens-in-aus/
Therapeutic Goods Administration. (2026b, September 11). Sunscreen ingredients [Web page]. Retrieved October 24, 2026, from https://www.tga.gov.au/resources/explore-topic/sunscreens/sunscreen-ingredients
Therapeutic Goods (Permissible Ingredients) Determination (No. 3) 2026 (Cth). F2026L01382. https://www.legislation.gov.au/F2026L01382/latest/text
U.S. Food and Drug Administration. (2019, February 26). Sunscreen drug products for over-the-counter human use (Proposed rule, 84 Fed. Reg. 6204; Docket No. FDA-1978-N-0018). Federal Register. https://www.govinfo.gov/content/pkg/FR-2019-02-26/pdf/2019-03019.pdf
U.S. Food and Drug Administration. (2021, September 24). Proposed order (OTC000008): Amending over-the-counter (OTC) monograph M020: Sunscreen drug products for OTC human use. OTC Monographs@FDA. https://www.accessdata.fda.gov/scripts/cder/omuf/index.cfm
U.S. Food and Drug Administration. (2025, December 12). Proposed administrative order (OTC000039): Amending over-the-counter monograph M020: Sunscreen drug products for over-the-counter human use (Docket No. FDA-2025-N-6494; 90 Fed. Reg. 57765). https://www.accessdata.fda.gov/drugsatfda_docs/omuf/Order/supportDoc/OTC000039/Internal_Documents/2025.12.09%20ProposedOrder_BemotrizinolOTC000039_090026f88e15dab6.pdf
U.S. Food and Drug Administration. (2026, June 10). Final administrative order (OTC000039): Amending over-the-counter monograph M020: Sunscreen drug products for over-the-counter human use, and related information [Corrected version, August 10, 2026] (Docket No. FDA-2025-N-6494; 91 Fed. Reg. 35220). https://www.accessdata.fda.gov/drugsatfda_docs/omuf/Order/OTC000039_Final_Administrative_Order.pdf




